BAZ1B and breast cancer: Lundqvist et al. also demonstrated that a 1,25D3 analogue reduces aromatase expression by promoting dissociation of the co-modulator Williams syndrome transcription factor from the cyp19a1 promoter in breast cancer cells [36].